Suchergebnisse - "Clinical Trial, Phase III"

PubPharm (35)

1

enthalten in: Der Urologe. Ausg. A | 2020

2

First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO

enthalten in: Der Urologe. Ausg. A | 2017

von Rexer, H. | Ohlmann, C. | Gschwend, J. | +1

3

Adjuvant radiotherapy for lymph-node-positive prostate cancer with low tumor load after radical prostatectomy : Multicenter randomized phase III study of the effect of adjuvant radiotherapy in patients with prostate cancer with or without a positive margin after radical prostatectomy (RP) and lymph node metastasis with low tumor load (micrometastases, ≤ 2 lymph node macrometastases). ART-2 - study AP 61/10 of the AUO

enthalten in: Der Urologe. Ausg. A | 2017

von Rexer, H. | Bartkowiak, D.

4

First-line therapy for locally advanced or metastatic urothelial carcinoma : A randomized, controlled phase III trial comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy only in patients with advanced or metastatic urothelial carcinoma (keynote 361-AB 54/16 of the AUO)

enthalten in: Der Urologe. Ausg. A | 2017

von Rexer, H. | Ohlmann, C. | Retz, M.

5

First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO

enthalten in: Der Urologe. Ausg. A | 2017

von Rexer, H. | Bedke, J.

6

Phase III study for local or locally advanced prostate cancer : Randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO

enthalten in: Der Urologe. Ausg. A | 2017

von Rexer, H. | Graefen, M.

7

Adjuvant study of high-risk muscle invasive urothelial carcinoma : Open-label, multicenter, randomized phase III study with atezolizumab (anti-PD-L1 antibody) as adjuvant therapy compared with observation in patients with high-risk muscle invasive urothelial carcinoma after surgical resection (IMvigor010)- study AB 53/15 of the AUO

enthalten in: Der Urologe. Ausg. A | 2016

von Rexer, H. | Retz, M. | Albers, P.

8

First-line treatment for advanced renal cell carcinoma : A phase 3, open-label, randomized study of Atezolizumab (Anti-PD-L1-Antibody) in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma ("IMmotion") - AN 37/15 der AUO

enthalten in: Der Urologe. Ausg. A | 2016

von Rexer, H. | Doehn, C.

9

First-line treatment of unresectable, stage IV transitional cell carcinoma

enthalten in: Der Urologe. Ausg. A | 2016

von Rexer, H. | Ohlmann, C.

10

Study for the treatment of nonmuscle invasive bladder cancer : A phase III efficacy trial for intravesical instillation of mistletoe extract in superficial bladder cancer (TIM) - AB 40/11 of the AUO

enthalten in: Der Urologe. Ausg. A | 2016

von Rexer, H. | Geschäftsstelle der AUO